Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1984)
  2. Solid Tumor Oncology Division (1616)
  3. GSK Faculty (762)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (413)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2092)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (89)
  5. Editorial (80)
  6. Guidelines (36)
  7. Correspondence (24)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1984)
  2. Solid Tumor Oncology Division (1616)
  3. GSK Faculty (762)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (80)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1668)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (209)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4627)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial
    Meeting Abstract

    Aghajanian, C.; Schmalfeldt, B.; Okamoto, A.; Reuss, A.; Kim, J. W.; Marquina Ospina, G.; Ayhan, A.; Salutari, V.; Lebreton, C.; Labudovic, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors
    Meeting Abstract

    Ray-Coquard, I. L.; Liu, J. F.; O'Malley, D.; Oaknin, A.; Pothuri, B.; Lorusso, D.; Eskander, R. N.; Westin, S.; Lakhani, N. J.; McKean, W. B.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163)
    Meeting Abstract

    Saba, N. F.; Flamand, Y.; Lin, D. T.; Chung, C. H.; McDonald, M. W.; Flampouri, S.; Khan, S. A.; Snyderman, C. H.; Hanna, E.; El-Sayed, Y. H.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Global, phase Ib dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced (a) endometrial cancer (EC) that progressed on platinum-based chemotherapy (CTx) and an anti-PD-(L)1 immunotherapy (IO)
    Meeting Abstract

    Lee, J. Y.; Hasegawa, K.; Kim, B. G.; Corr, B. R.; Kondo, S.; Suzuki, S.; Yunokawa, M.; Miller, D. S.; Tamai, T.; Dutta, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)
    Meeting Abstract

    Lee, J. M.; MacLaughlan, S.; Matei, D.; Song, M.; Brubaker, L.; Rimmel, B.; Eskander, R. N.; Kyi, C.; Williams, H.; Duska, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)
    Meeting Abstract

    Friedman, C.; De Burgh Williams, A.; Lopez, J. S.; Ouali, K.; Middleton, M. R.; Thistlethwaite, F.; Hamid, O.; Izar, B.; Moreno Garcia, V.; Johnson, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
    Meeting Abstract

    Schram, A. M.; Lopes, G.; El-Khoueiry, A. B.; Fontana, E.; Karasic, T. B.; Kummar, S.; Lorusso, P.; Gregorc, V.; Millward, M.; Aix, S. P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study
    Meeting Abstract

    Oaknin, A.; Ang, J. E.; Rha, S. Y.; Yonemori, K.; Kristeleit, R.; Lin, C. C.; Satoh, T.; Garcia, P. E.; Sendur, M. A. N.; Rodríguez, L. M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study
    Meeting Abstract

    Danska-Bidzinska, A.; Makker, V.; Salutari, V.; Ayhan, A.; Romero, I.; Levy, T.; McCormack, M.; Baurain, J. F.; Mach, P.; Cadoo, K. A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save